While the Medicare Price Negotiations component of the Inflation Reduction Act (IRA) has garnered a lot of attention, the Part D benefit redesign – and associated shifts in stakeholder liability – is poised to be just as disruptive to standard business practices.
The IRA mandates a series of changes to the Part D program that will shift financial liability from patients to plans and drug manufacturers. Specific highlights include:
- Implementation of an annual $2000 out-of-pocket (OOP) spending cap for patients
- Expanded subsidies for low-income enrollees
- Increased Part D plan liability in the catastrophic phase
- Limits on annual premium increases
During this webinar, we explored:
- Anticipated changes to Rx demand due to increased affordability
- Potential payer responses to risk of greater utilization and increasing liability
- Strategies and considerations to re-think Part D contracting in this new post-IRA world
- Considerations around geographic targeting based on affordability dynamics
- Implications to payer, HCP, and patient engagement
Hear Amber Gilbert, Tanya Swift, and Lisa Cashman discuss the importance of understanding the implication.
